‘New GSK’ Raises Outlook After Shingrix Hits New Heights
Vaccine Leads Growth In New Slimline Company
The company looks to be building momentum at last, with four more late-stage trial readouts expected in the second half of 2022.
You may also be interested in...
Phase III data for a vaccine combining Bexsero and Menveo demonstrated non-inferiority. GSK hopes to file it for approval soon, while Pfizer’s candidate has an October FDA action date.
The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.
The company announced data showing the two-antibody drug had strong activity against Omicron BA.4, BA.5 and BA.2.12.1, but on the US market it would compete against oral drugs.